The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ecteinascidin-743 (ET-743) in Taxane (T)/Anthracycline (A) Pretreated Advanced/Metastatic Breast Cancer (A/MBC) Patients (Pts): Preliminary Results with the 24 Hour (H) Continuous Infusion (CI) Q3week Schedule.
 
Martin Valera Consunji
No Relationships to Disclose
 
Spencer Behr
No Relationships to Disclose
 
Andrew H. Ko
Honoraria - Advance Medical; Med IQ; Medscape; Peerview
Consulting or Advisory Role - ARMO Biosciences; EMD Serono; Genentech/Roche; Halozyme; Incyte; Merrimack; New B Innovation; Seagen
Speakers' Bureau - Clinical Care Options
Research Funding - AbGenomics International (Inst); Acerta Pharma (Inst); Aduro Biotech (Inst); Apexigen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Halozyme (Inst); Merck (Inst); Merrimack (Inst); PRISM BioLab (Inst)
 
Margaret A. Tempero
Consulting or Advisory Role - AstraZeneca; Asuragen; Bayer; Celgene (Inst); EMD Serono; Halozyme (Inst); Lilly; Myriad Genetics; Nucana; Pfizer; Pfizer / EMD Sorono; Portola Pharmaceuticals; Roche/Genentech; Targovax
Research Funding - Celgene (Inst); Halozyme (Inst)
Travel, Accommodations, Expenses - Celgene; EMD Serono; Halozyme; Lilly; Myriad Genetics; Pfizer; Targovax
 
Pelin Cinar
Research Funding - Newlink Genetics
 
Zhen J. Wang
Stock and Other Ownership Interests - Nextrast
Patents, Royalties, Other Intellectual Property - Nextrast (I)